Parkinson disease: Research update and clinical management

Southern Medical Journal

Volumn 105, Issue 12, 2012, Pages 650-656

  Fritsch, Thomas ^a,b,c   Smyth, Kathleen A ^a,b,c   Wallendal, Maggie S ^a,b,c   Hyde, Trevor ^a,b,c   Leo, Gary ^a,b,c   Geldmacher, David S ^a,b,c  

^a AURORA SINAI MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Parkinson disease; practice recommendations; research update

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; AMITRIPTYLINE PLUS PERPHENAZINE; AMOXAPINE; ASCENDIN; BENZODIAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIAZEPAM; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; ISOCARBOXAZID; LORAZEPAM; LOXAPINE SUCCINATE; MESORIDAZINE; MESORIDAZINE BESYLATE; MOBANE; MOLINDONE; OLANZAPINE; PERPHENAZINE; PHENELZINE; PIMOZIDE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; PROMETHAZINE; PROXLIXIN; RIVASTIGMINE; THIORIDAZINE; TIOTIXENE; TRANYLCYPROMINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; ANXIETY DISORDER; AUTONOMIC NERVOUS SYSTEM; BECK DEPRESSION INVENTORY; BEHAVIOR CHANGE; CLINICAL FEATURE; CLINICAL RESEARCH; COGNITION; DEMENTIA; DEPRESSION; DRUG CONTRAINDICATION; DYSKINESIA; ENVIRONMENTAL FACTOR; HAMILTON SCALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHOLOGY; NEUROPROTECTION; NEUROPSYCHIATRY; PARKINSON DISEASE; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PSYCHOSIS; REVIEW; RISK FACTOR; SLEEP DISORDER; SYMPTOMATOLOGY; UNITED STATES;

DISEASE PROGRESSION; DOPAMINE AGENTS; HUMANS; PARKINSON DISEASE; PROGNOSIS; QUALITY OF LIFE; RISK FACTORS; UNITED STATES;

EID: 84871536947     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318273a60d     Document Type: Review

References (39)

1. De Lau LLL, Breteler MMB. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535.
2. Wright Willis A, Evanoff BA, Lian M, et al. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology 2010;34:143-151.
3. de Rijk M, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15.
4. Jankovic J. Pathophysiology and clinical assessment, in Pahwa R, Lyons KE (eds): Handbook of Parkinson's Disease, 4th ed. New York, Informa Healthcare, 2007, pp 49-75.
5. Pahwa R, Lyons KE. Handbook of Parkinson's Disease. New York, Informa Healthcare, 2007.
6. Jancovik J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
7. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease. Arch Neurol 2002;59:1724-1728.
8. Alves G, Wentzel-Larsen T, Aarsland D, et al. Progression of motor impairment and disability in Parkinson disease. Neurology 2005;65: 1436-1441.
9. Zgaljardic DJ, Borod JC, Foldi NS, et al. An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease. J Clin Exp Neuropsychol 2006;28:1127-1144.
10. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology 2006;66:996-1002.
11. Crum RM, Anthony JC, Bassett SS, et al. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 2012;307:883-985.
12. Geldmacher DS. Dementia with Lewy bodies: diagnosis and clinical approach. Cleve Clin J Med 2004:71;789-800.
13. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008;23:1889-1896.
14. Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 2005;112:201-207.
15. Dewey RB. Autonomic dysfunction and management, in Pahwa R, Lyons KE (eds): Handbook of Parkinson's Disease, 4th ed. New York, Informa Healthcare, 2007, pp 77-90.
16. Haehner A, Boesveldt S, Berendse HW, et al. Prevalence of smell loss in Parkinson's diseaseVa multicenter study. Parkinsonism Relat Disord 2009;15:490-494.
17. Ponsen MM, Stoffers D, Twisk JWR, et al. Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord 2009;24:1060-1065.
18. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord 2002;17:775-781.
19. Mehta SH, Morgan JC, Sethi KD. Sleep disorders associated with Parkinson's disease: role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectrums 2008;13:6-11.
20. Yuan-Yang L, Siegel JM. Physiological and anatomical link between Parkinson-like disease and REM sleep behavior disorder. Mol Neurobiol 2003;27:137-151.
21. Priyadarshi A, Khuder SA, Schaub EA, et al. Environmental risk factors and Parkinson's disease: a meta-analysis. Environ Res 2001;86:122-127.
22. Priyadarshi A, Khuder SA, Schuab EA, et al. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000; 21:435-440.
23. Hernán MA, Takkouche B, Caamano-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
24. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-1898.
25. Hawkes CH, Del Tredici K, Braak H. Review: Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007;33:599-614.
26. Dickson DW, Fujishiro H, Delledone A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008:115;437-444.
27. Kalaitzakis ME, Graeber MB, Gentleman SM, et al. Controversies over the staging of >-synuclein pathology in Parkinson disease. Acta Neuropathol 2008;116:125-128.
28. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidencebased review). Neurology 2006;66:983-995.
29. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181-187.
30. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:968-975.
31. Suchowesky O, Gronset G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Neurology 2006;66:976-982.
32. Clarke CE. Medical management of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;72:i22Yi27.
33. Goodwin VA, Richards SH, Taylor RS, et al. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disorder 2008;23:631-640.
34. LSVT: rehabilitative therapy for people with Parkinson's. http://www.lsvtglobal.com. Accessed June 14, 2012.
35. Ebersbach G, Ebersbach A, Edler D, et al. Comparing exercise in Parkinson's disease: the Berlin LSVT BIG study. Mov Disord 2010; 25:1902-1908.
36. Hackney ME, Earhart GM. Tai chi improves balance and mobility in people with Parkinson disease. Gait Posture 2008;28:456-460.
37. Fuzhong L, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012;366:511-519.
38. Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Neurology 2006;2:136-146.
39. Kroll C. Statistics on Parkinson's. http://www.pdf.org/en/parkinson- statistics. Accessed April 30, 2012.